Durham, North Carolina — According to state and local economic development sources Adverum Biotechnologies plans to invest $82,800,000.00 to build out 174,000 square feet of new space in Durham. The company plans to occupy the new space in Durham, on or about May 1, 2022. According to the company website Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients.

To learn more about Adverum Biotechnologies, visit http://adverum.com/

Company Contact:
Laurent Fischer, Chief Executive Officer
https://www.linkedin.com/in/laurent-fischer-bb72422/
650-656-9323

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved